Bioventix PLC is a leading biotechnology company, representing values of innovation, excellence, and integrity. With a strong commitment to quality and scientific advancement, Bioventix is dedicated to delivering high-quality products and services in the field of medical diagnostics. The company's corporate philosophy revolves around sustained growth, strong customer relationships, and long-term shareholder value. Bioventix PLC aims to make impactful contributions to the healthcare industry through the development of novel and highly specific antibodies, leading to improved diagnostic testing capabilities. Through its dedication to ethical business practices and cutting-edge research, Bioventix PLC continues to be a trusted and influential player in the biotech sector.

Bioventix PLC is primarily present in the United Kingdom, where it is headquartered. As a global company, Bioventix also has a significant presence in other regions around the world. With a strong international footprint, the company has operations in various countries, including the United States, Europe, and Asia. Its expanded reach allows Bioventix to serve a diverse customer base and capitalize on growth opportunities in different markets. With its commitment to innovation and expertise in the healthcare sector, Bioventix PLC continues to expand its presence and make a positive impact on the global stage.

Bioventix PLC has achieved several significant milestones. Some notable achievements include developing and commercializing a range of high-quality antibodies for use in the diagnostics market. These antibodies have gained widespread recognition and are widely used by major diagnostics companies globally. Additionally, Bioventix PLC has successfully established long-term partnerships and licensing agreements with key players in the industry. The company's innovative products and reliable services have played a pivotal role in enhancing diagnostic accuracy, improving patient outcomes, and ultimately driving growth and profitability for both Bioventix PLC and its partners.

Bioventix PLC is a renowned biotechnology company based in the United Kingdom. Founded in 2003, Bioventix specializes in the development and supply of high-affinity monoclonal antibodies for use in clinical diagnostics. With a strong focus on the creation of innovative and valuable products, Bioventix has established itself as a leader in the field. The company's success can be attributed to its dedicated team of talented scientists and its commitment to delivering accurate and reliable diagnostic solutions. Bioventix PLC continues to grow and expand its portfolio of products, aiming to contribute to advancements in healthcare and improve patient outcomes.

Some of the main competitors of Bioventix PLC in the market include Abcam Plc, Novartis AG, and Roche Holding AG.

Bioventix PLC is primarily active in the biotechnology and pharmaceutical industries.

The business model of Bioventix PLC revolves around the development and supply of high quality antibodies used in the in vitro diagnostics market. As a leading biotechnology company, Bioventix specializes in the creation of monoclonal antibodies that can accurately detect specific molecules in blood samples. These antibodies are crucial for various diagnostic applications, including medical testing for conditions like thyroid disorders, vitamin deficiencies, and hormone-related diseases. With its expertise in antibody development and a strong emphasis on product quality, Bioventix PLC has established itself as a trusted provider in the diagnostics industry, catering to the needs of healthcare professionals and patients worldwide.

Bioventix P/E-luku on 16,89.

Bioventix KUV on 10,40.

AlleAktien Laatuscore Bioventix on 9/10.

odotettu Bioventix liikevaihto on 14,65 milj. GBP.

odotettu Bioventix voitto on 9,02 milj. GBP.

Bioventix PLC specializes in the development of highly specialized antibodies for diagnostic, pharmaceutical research, and development. The company's business model is based on the production and sale of antibodies for disease diagnostics and analysis of blood samples for biomedical research. Bioventix provides antibodies for diagnostic tests, such as Troponin I, to detect biomarkers for heart conditions. They also provide antibodies for Vitamin D tests. In the pharmaceutical sector, Bioventix develops antibodies for cancer research and BNP antibodies for heart disease treatment. The company focuses on manufacturing and selling specialized antibodies, serving diagnostic companies. Their advantage lies in developing antibodies in limited quantities, providing precise and reliable results. They have an experienced team and extensive antibody library for efficient production. Overall, Bioventix has a successful business model and is expected to continue thriving in the market.

Bioventix maksaa osinkoa 1,26 GBP, joka jaetaan erässä vuoden aikana.

Osinkoa ei voida tällä hetkellä laskea Bioventix:lle tai yhtiö ei maksa osinkoa.

Bioventix:n ISIN on GB00B4QVDF07.

Bioventix:n WKN on A113DD.

Bioventix:n tunnus on BVXP.L.

Viimeisen 12 kuukauden aikana Bioventix maksoi osinkoa 1,55 GBP edestä. Tämä vastaa noin 5,39 % osinkotuottoa. Seuraavan 12 kuukauden aikana Bioventix maksanee ennusteiden mukaan 1,81 GBP osingon.

Bioventix:n tämänhetkinen osinkotuotto on 5,39 %.

Bioventix maksaa osinkoa neljännesvuosittain. Osingot jaetaan kuukausina toukokuu, joulukuu, toukokuu, joulukuu.

Bioventix maksoi osinkoa joka vuosi viimeisten 13 vuoden aikana.

Seuraavalle 12 kuukaudelle odotetaan 1,81 GBP suuruisia osinkoja. Tämä vastaa 6,30 % osinkotuottoa.

Bioventix kuuluu sektoriin 'Terveys'.

Saadaksesi viimeisimmän Bioventix osingon 21.11.2024, jonka suuruus on 0,87 GBP, sinun oli oltava omistanut osakkeen ennen ex-päivää, joka oli 7.11.2024.

Viimeisin osinko maksettiin 21.11.2024.

Vuonna 2024 Bioventix maksoi 1,52 GBP osinkoina.

Bioventix:n osingot maksetaan GBPssa.